Viking Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Viking Therapeutics has a total shareholder equity of $911.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $937.9M and $26.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$930.44m |
| Equity | US$911.45m |
| Total liabilities | US$26.44m |
| Total assets | US$937.89m |
Recent financial health updates
We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow
Dec 23
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07Recent updates
We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow
Dec 23Viking Therapeutics: Holiday Gift
Dec 19Viking Stock Pops, Then Drops On Latest Obesity/MASH Data: Why I'm Still Bullish
Dec 05Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Nov 04Viking Therapeutics: Lots Of Positives
Oct 28Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Sep 25Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Aug 30Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
Jul 25We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Viking Therapeutics: Playing Second Fiddle To Madrigal
Aug 30We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Jul 13Revisiting Viking Therapeutics
Apr 20We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Apr 12We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Dec 17Viking Therapeutics: Remaining Bullish And Sticking To My Plan
Aug 27Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder
Jun 17Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?
Jan 13Financial Position Analysis
Short Term Liabilities: VKTX's short term assets ($936.6M) exceed its short term liabilities ($25.7M).
Long Term Liabilities: VKTX's short term assets ($936.6M) exceed its long term liabilities ($755.0K).
Debt to Equity History and Analysis
Debt Level: VKTX is debt free.
Reducing Debt: VKTX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VKTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: VKTX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 25% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 08:22 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Viking Therapeutics, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Luchini | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Julian Harrison | BTIG |